Average Co-Inventor Count = 7.06
ph-index = 14
The patent ph-index is calculated by counting the number of publications for which an author has been cited by other authors at least that same number of times.
Company Filing History:
1. Ambrx, Inc. (36 from 113 patents)
2. Merck Sharp + Dohme Corp. (4 from 2,405 patents)
3. Elanco US Inc. (3 from 42 patents)
4. Ambryx, Inc. (1 from 1 patent)
5. Eli Lilly and Company (4,442 patents)
37 patents:
1. 11993637 - Modified FGF-21 polypeptides with non-naturally encoded amino acids
2. 11786578 - Modified relaxin polypeptides and their uses
3. 11773150 - Antibody peptide conjugates that have agonist activity at both the glucagon and glucagon-like peptide 1 receptors
4. 11542310 - Modified bovine G-CSF polypeptides and their uses
5. 11510993 - Antibody drug conjugate for anti-inflammatory applications
6. 11459392 - Anti-CD70 antibody drug conjugates
7. 11439710 - Nucleic acids encoding modified relaxin polypeptides
8. 11311605 - Methods of treating heart failure and fibrotic disorders using modified relaxin polypeptides
9. 10961291 - Modified FGF-21 polypeptides and their uses
10. 10800826 - Antibody peptide conjugates that have agonist activity at both the glucagon and glucagon-like peptide 1 receptors
11. 10800856 - Prostate-specific membrane antigen antibody drug conjugates
12. 10751391 - Methods of treatment using modified relaxin polypeptides comprising a non-naturally encoded amino acid
13. 10702588 - Modified relaxin polypeptides comprising a non-naturally encoded amino acid in the A chain
14. 10550190 - Phosphate based linkers for intracellular delivery of drug conjugates
15. 10377805 - Modified FGF-21 polypeptides comprising non-naturally encoding amino acids and their uses